FDA investigates risk of secondary malignancies with CAR T-cell therapy
Regulatory NewsJoanne S. Eglovitch
Advanced therapies/cell and gene therapyBiologics/ biosimilars/ vaccinesChemistry, Manufacturing and Controls (CMC)ComplianceNorth AmericaQuality Assurance and ControlRegulatory Intelligence/Policy